Medicare's insulin affordability crisis may be more complex than simple cost barriers suggest. While the $35 monthly cap dramatically reduced financial burden, it failed to translate into the expected improvements in diabetes management that health economists predicted. This disconnect reveals critical gaps in our understanding of medication adherence drivers among older adults with diabetes.
The policy delivered substantial financial relief across 2.86 million Medicare insulin users, slashing average out-of-pocket costs from $22.95 to $18.16 per month—a 21% reduction. More dramatically, the variation in yearly insulin costs dropped 48%, eliminating the coverage gap periods when patients previously faced costs exceeding $100 monthly. Before implementation, 13% of insulin fills would have exceeded the $35 threshold, but virtually none did afterward.
Yet insulin fills, adherence rates, and treatment persistence remained essentially unchanged, challenging the prevailing assumption that cost barriers are the primary obstacle to optimal diabetes care. This suggests that factors beyond affordability—such as clinical inertia, side effect concerns, complex dosing regimens, or health literacy gaps—may be equally important barriers to consistent insulin use among Medicare beneficiaries.
The findings represent both policy success and analytical puzzle. While the cap achieved its immediate goal of cost reduction, the absence of corresponding health behavior improvements indicates that sustainable diabetes management requires multifaceted interventions beyond financial relief. For the broader Medicare population approaching insulin dependence, this suggests that future policy efforts should address the full spectrum of adherence barriers, not just economic ones.